Delivery Order SPE2DB22D3102-SPE2DB25FL2NE
- Not listed
- The Defense Logistics Agency awarded a $3,341.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of September 2, 2025. This is a non-set-aside, competitively awarded contract with performance in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026, which...
- The Defense Logistics Agency awarded a $1,654.33 firm fixed price delivery order to AmerisourceBergen Drug Corp for ProQuad vials on August 20, 2025, with a completion date of September 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999.99 million and extending through December 2026. The order will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ProQuad vials valued at $1,687.48, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The place of performance is located in Conshohocken,...
- The Defense Logistics Agency awarded a $1,687.48 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for ProQuad vials with a completion date of August 29, 2025. This firm fixed-price, non-set-aside contract is being performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. As a child order under a larger contract vehicle, this delivery order leverages AmerisourceBergen's established relationships with DLA for pharmaceutical supply to...
- The Defense Logistics Agency awarded a $2,686.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ProQuad vials on August 14, 2025, with an ultimate completion date of September 5, 2025. This contract represents a non-competitive delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. ProQuad is a combination vaccine protecting against measles, mumps, rubella, and...
- The Defense Logistics Agency awarded a $1,670.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of August 15, 2025. This is a non-set-aside, competitively awarded contract executed on July 25, 2025, with performance at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $16,543.30 delivery order (Contract 4569422403) to AmerisourceBergen Drug Corp for ProQuad vials, with an ultimate completion date of September 26, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 16, 2025, for ProQuad vials with a ceiling value of $1,687.48 and a firm fixed price structure. The contract is scheduled for ultimate completion by August 6, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This is a non-set-aside, competitively awarded delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $6,055.26 to AmerisourceBergen Drug Corp for ProQuad vials on August 5, 2025, with an ultimate completion date of August 26, 2025. This competitively awarded, firm fixed price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The place of performance is located in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ProQuad vials valued at $1,687.48, with an ultimate completion date of September 23, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to the pharmaceutical distributor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's existing contract vehicle with DLA for pharmaceutical and...
- SPE2DB22D3102Indefinite Delivery Contract
- SPE2DB22D3102-SPE2DB25FL2NEDelivery Order
The Defense Logistics Agency awarded a $1,670.90 firm fixed price delivery order to AmerisourceBergen Drug Corp for ProQuad vials on August 12, 2025, with an ultimate completion date of September 3, 2025. This is an unset-aside, competitively awarded contract with performance in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion and extending through December 2026, which serves as the primary pharmaceutical supply vehicle for military healthcare worldwide. ProQuad is a combination vaccine providing immunization against measles, mumps, rubella, and varicella, making this delivery order part of the critical medical supply chain supporting Defense Health Agency operations and broader federal military medical programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, maintains a substantial federal contract portfolio with DLA covering a comprehensive range of pharmaceutical products, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The company's demonstrated capability to deliver both small-value and high-value medical supply orders through open competition underscores its significance as a key vendor for federal military healthcare procurement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 8/12/25 |